Share Price and Basic Stock Data
Last Updated: December 18, 2025, 11:57 pm
| PEG Ratio | 2.50 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lactose (India) Ltd operates in the pharmaceuticals sector, focusing primarily on lactose products used in various applications. The company has shown a notable upward trend in revenues, with sales reported at ₹66 Cr for FY 2023 and rising to ₹114 Cr by FY 2024, marking a robust year-on-year growth. The trailing twelve months (TTM) revenue stands at ₹127 Cr, indicating a consistent demand for its products. Quarterly figures reveal fluctuations, with the highest sales of ₹32.60 Cr recorded in December 2023, followed by a slight decline to ₹29.40 Cr in March 2024. This suggests potential seasonality in sales or supply chain challenges. With a market capitalization of ₹151 Cr and a price-to-earnings (P/E) ratio of 33.4, Lactose appears to be priced at a premium compared to many peers in the sector, reflecting investor expectations of future growth.
Profitability and Efficiency Metrics
Profitability metrics for Lactose (India) Ltd indicate a mixed performance. The operating profit margin (OPM) has fluctuated, peaking at 27% in FY 2022 but declining to 15% by FY 2025. This decline could raise concerns about cost management and pricing power in a competitive environment. The net profit for FY 2024 was reported at ₹7 Cr, which shows improvement compared to ₹1 Cr in FY 2023, but the net profit margin fell to 4.3%, highlighting challenges in converting revenue growth into bottom-line profitability. Return on equity (ROE) stands at 9.69%, which is relatively modest, suggesting that while the company is generating profits, there is room for improvement in effectively utilizing shareholder equity. Additionally, the interest coverage ratio (ICR) of 3.02x indicates that the company is comfortably able to meet its interest obligations, which is a positive sign for investors.
Balance Sheet Strength and Financial Ratios
Lactose’s balance sheet reveals a cautious approach to leveraging, with total borrowings reported at ₹54 Cr against reserves of ₹50 Cr. This level of debt indicates that the company is not overly reliant on external financing, which can be a strength in uncertain economic conditions. The current ratio stands at 1.28, suggesting that Lactose maintains a healthy liquidity position, able to cover short-term liabilities with current assets. However, the cash conversion cycle (CCC) of 165 days shows that the company takes a considerable amount of time to convert its investments in inventory and receivables back into cash, which could strain liquidity if not managed effectively. The price-to-book value ratio (P/BV) of 1.90x suggests that the stock is trading at a premium to its book value, which may reflect investor optimism about future growth prospects.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lactose (India) Ltd shows a significant promoter holding of 53.65%, which indicates strong control by the founding members. This can be a double-edged sword; while it reflects confidence from the promoters, it may also limit the influence of minority shareholders. Institutional investment is minimal, with foreign institutional investors (FIIs) absent and domestic institutional investors (DIIs) holding just 0.62%. This lack of institutional backing may suggest cautious sentiment among larger investors. The public holding stands at 45.73%, with a growing number of shareholders, which rose from approximately 15,940 in December 2022 to 16,810 by September 2025. This increase indicates a growing interest from retail investors, which could be a positive sign for market sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Lactose (India) Ltd faces both opportunities and challenges. On the positive side, the company’s revenue trajectory suggests strong market demand, particularly if it can stabilize its profitability metrics. However, risks include fluctuating margins and a high cash conversion cycle, which could impede operational efficiency. Investors should also be cautious about the company’s reliance on a concentrated promoter holding, which could impact governance and decision-making. The pharmaceutical sector is inherently competitive, and Lactose must navigate these challenges while capitalizing on growth opportunities. With a current market context that favors innovation and scalability, Lactose’s ability to adapt and manage its financial health will be crucial for long-term investor confidence and stock performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 147 Cr. | 116 | 235/84.3 | 32.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,239 Cr. | 389 | 479/192 | 87.8 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.8 Cr. | 45.5 | 89.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.2 Cr. | 32.9 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,006.85 Cr | 1,144.50 | 52.26 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9.62 | 13.17 | 17.02 | 25.99 | 27.47 | 24.43 | 32.60 | 29.40 | 29.46 | 30.45 | 28.72 | 27.77 | 39.58 |
| Expenses | 7.34 | 10.82 | 14.29 | 21.99 | 23.70 | 21.04 | 26.88 | 23.28 | 23.88 | 25.44 | 25.75 | 24.36 | 35.11 |
| Operating Profit | 2.28 | 2.35 | 2.73 | 4.00 | 3.77 | 3.39 | 5.72 | 6.12 | 5.58 | 5.01 | 2.97 | 3.41 | 4.47 |
| OPM % | 23.70% | 17.84% | 16.04% | 15.39% | 13.72% | 13.88% | 17.55% | 20.82% | 18.94% | 16.45% | 10.34% | 12.28% | 11.29% |
| Other Income | 0.23 | 0.20 | 0.16 | 0.14 | 0.28 | 0.26 | 0.28 | 0.31 | 0.22 | 0.30 | 0.56 | 0.37 | 0.41 |
| Interest | 1.24 | 1.31 | 1.55 | 1.84 | 1.55 | 1.31 | 1.21 | 1.17 | 1.26 | 1.37 | 1.64 | 1.84 | 1.22 |
| Depreciation | 1.16 | 1.17 | 1.17 | 1.19 | 1.19 | 1.20 | 1.20 | 1.63 | 1.31 | 1.33 | 1.35 | 1.39 | 1.37 |
| Profit before tax | 0.11 | 0.07 | 0.17 | 1.11 | 1.31 | 1.14 | 3.59 | 3.63 | 3.23 | 2.61 | 0.54 | 0.55 | 2.29 |
| Tax % | 18.18% | -14.29% | 11.76% | 20.72% | 26.72% | 28.95% | 27.02% | 33.88% | 29.72% | 22.22% | 59.26% | -18.18% | 34.50% |
| Net Profit | 0.09 | 0.09 | 0.14 | 0.89 | 0.96 | 0.81 | 2.63 | 2.40 | 2.27 | 2.03 | 0.22 | 0.64 | 1.50 |
| EPS in Rs | 0.07 | 0.07 | 0.11 | 0.71 | 0.76 | 0.64 | 2.09 | 1.91 | 1.80 | 1.61 | 0.17 | 0.51 | 1.19 |
Last Updated: August 19, 2025, 12:44 pm
Below is a detailed analysis of the quarterly data for Lactose (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 39.58 Cr.. The value appears strong and on an upward trend. It has increased from 27.77 Cr. (Mar 2025) to 39.58 Cr., marking an increase of 11.81 Cr..
- For Expenses, as of Jun 2025, the value is 35.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 24.36 Cr. (Mar 2025) to 35.11 Cr., marking an increase of 10.75 Cr..
- For Operating Profit, as of Jun 2025, the value is 4.47 Cr.. The value appears strong and on an upward trend. It has increased from 3.41 Cr. (Mar 2025) to 4.47 Cr., marking an increase of 1.06 Cr..
- For OPM %, as of Jun 2025, the value is 11.29%. The value appears to be declining and may need further review. It has decreased from 12.28% (Mar 2025) to 11.29%, marking a decrease of 0.99%.
- For Other Income, as of Jun 2025, the value is 0.41 Cr.. The value appears strong and on an upward trend. It has increased from 0.37 Cr. (Mar 2025) to 0.41 Cr., marking an increase of 0.04 Cr..
- For Interest, as of Jun 2025, the value is 1.22 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.84 Cr. (Mar 2025) to 1.22 Cr., marking a decrease of 0.62 Cr..
- For Depreciation, as of Jun 2025, the value is 1.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.39 Cr. (Mar 2025) to 1.37 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 2.29 Cr.. The value appears strong and on an upward trend. It has increased from 0.55 Cr. (Mar 2025) to 2.29 Cr., marking an increase of 1.74 Cr..
- For Tax %, as of Jun 2025, the value is 34.50%. The value appears to be increasing, which may not be favorable. It has increased from -18.18% (Mar 2025) to 34.50%, marking an increase of 52.68%.
- For Net Profit, as of Jun 2025, the value is 1.50 Cr.. The value appears strong and on an upward trend. It has increased from 0.64 Cr. (Mar 2025) to 1.50 Cr., marking an increase of 0.86 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.19. The value appears strong and on an upward trend. It has increased from 0.51 (Mar 2025) to 1.19, marking an increase of 0.68.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:27 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22 | 24 | 34 | 36 | 31 | 41 | 40 | 35 | 46 | 66 | 114 | 116 | 137 |
| Expenses | 21 | 19 | 24 | 24 | 25 | 31 | 31 | 29 | 34 | 54 | 95 | 99 | 121 |
| Operating Profit | 1 | 5 | 10 | 11 | 6 | 10 | 9 | 6 | 12 | 11 | 19 | 17 | 16 |
| OPM % | 5% | 22% | 30% | 32% | 18% | 24% | 23% | 18% | 27% | 17% | 17% | 15% | 12% |
| Other Income | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| Interest | 1 | 3 | 4 | 4 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 6 | 6 |
| Depreciation | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 |
| Profit before tax | 0 | 1 | 4 | 4 | -3 | 1 | 0 | -3 | 3 | 1 | 10 | 7 | 7 |
| Tax % | 60% | 42% | 28% | 36% | -52% | 33% | 30% | -24% | 23% | 18% | 30% | 25% | |
| Net Profit | 0 | 0 | 3 | 3 | -1 | 1 | 0 | -2 | 2 | 1 | 7 | 5 | 5 |
| EPS in Rs | 0.04 | 0.59 | 3.17 | 2.87 | -1.32 | 0.71 | 0.07 | -2.17 | 1.95 | 0.96 | 5.39 | 4.10 | 3.59 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -133.33% | 200.00% | -100.00% | 200.00% | -50.00% | 600.00% | -28.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | 333.33% | -300.00% | 300.00% | -250.00% | 650.00% | -628.57% |
Lactose (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 24% |
| 3 Years: | 36% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 136% |
| 3 Years: | 29% |
| TTM: | -46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 39% |
| 3 Years: | 20% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 6% |
| 3 Years: | 10% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 3:55 pm
Balance Sheet
Last Updated: December 10, 2025, 4:35 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 10 | 10 | 10 | 10 | 11 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 7 | 7 | 12 | 17 | 22 | 24 | 24 | 24 | 27 | 28 | 35 | 46 | 50 |
| Borrowings | 23 | 39 | 37 | 34 | 38 | 36 | 39 | 46 | 41 | 38 | 39 | 57 | 54 |
| Other Liabilities | 22 | 25 | 26 | 24 | 13 | 11 | 10 | 7 | 10 | 22 | 14 | 18 | 21 |
| Total Liabilities | 60 | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 | 138 |
| Fixed Assets | 28 | 62 | 61 | 64 | 63 | 60 | 62 | 59 | 59 | 56 | 55 | 52 | 56 |
| CWIP | 15 | 1 | 1 | 1 | 0 | 1 | 0 | 4 | 0 | 0 | 0 | 10 | 12 |
| Investments | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Other Assets | 16 | 15 | 21 | 20 | 19 | 20 | 22 | 25 | 30 | 45 | 46 | 71 | 71 |
| Total Assets | 60 | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 | 138 |
Below is a detailed analysis of the balance sheet data for Lactose (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 4.00 Cr..
- For Borrowings, as of Sep 2025, the value is 54.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 57.00 Cr. (Mar 2025) to 54.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 21.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.00 Cr. (Mar 2025) to 21.00 Cr., marking an increase of 3.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 138.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 133.00 Cr. (Mar 2025) to 138.00 Cr., marking an increase of 5.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 56.00 Cr.. The value appears strong and on an upward trend. It has increased from 52.00 Cr. (Mar 2025) to 56.00 Cr., marking an increase of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 71.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 71.00 Cr..
- For Total Assets, as of Sep 2025, the value is 138.00 Cr.. The value appears strong and on an upward trend. It has increased from 133.00 Cr. (Mar 2025) to 138.00 Cr., marking an increase of 5.00 Cr..
However, the Borrowings (54.00 Cr.) are higher than the Reserves (50.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -22.00 | -34.00 | -27.00 | -23.00 | -32.00 | -26.00 | -30.00 | -40.00 | -29.00 | -27.00 | -20.00 | -40.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 125 | 83 | 96 | 91 | 63 | 62 | 64 | 67 | 90 | 69 | 49 | 68 |
| Inventory Days | 69 | 129 | 344 | 440 | 456 | 384 | 471 | 587 | 343 | 344 | 119 | 171 |
| Days Payable | 308 | 273 | 340 | 559 | 330 | 242 | 202 | 153 | 195 | 275 | 59 | 74 |
| Cash Conversion Cycle | -114 | -61 | 100 | -27 | 188 | 204 | 333 | 501 | 238 | 138 | 109 | 165 |
| Working Capital Days | -59 | -118 | -100 | -107 | 18 | 42 | 59 | 56 | 46 | 56 | 26 | 24 |
| ROCE % | -3% | 8% | 13% | 15% | 4% | 9% | 8% | 3% | 10% | 9% | 18% | 13% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 4.10 | 5.39 | 0.96 | 2.10 | -2.40 |
| Diluted EPS (Rs.) | 4.06 | 5.39 | 0.96 | 2.10 | -2.40 |
| Cash EPS (Rs.) | 8.38 | 9.54 | 4.68 | 5.57 | 1.64 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 46.66 | 37.41 | 32.22 | 31.20 | 30.68 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 46.66 | 37.41 | 32.22 | 31.20 | 30.68 |
| Revenue From Operations / Share (Rs.) | 92.46 | 90.47 | 52.26 | 36.49 | 30.57 |
| PBDIT / Share (Rs.) | 14.63 | 15.98 | 9.61 | 10.20 | 5.71 |
| PBIT / Share (Rs.) | 10.34 | 11.84 | 5.89 | 6.58 | 1.90 |
| PBT / Share (Rs.) | 5.50 | 7.68 | 1.16 | 2.52 | -2.86 |
| Net Profit / Share (Rs.) | 4.10 | 5.39 | 0.96 | 1.95 | -2.17 |
| PBDIT Margin (%) | 15.81 | 17.66 | 18.38 | 27.95 | 18.69 |
| PBIT Margin (%) | 11.18 | 13.08 | 11.26 | 18.02 | 6.22 |
| PBT Margin (%) | 5.94 | 8.48 | 2.22 | 6.89 | -9.35 |
| Net Profit Margin (%) | 4.43 | 5.96 | 1.83 | 5.33 | -7.08 |
| Return on Networth / Equity (%) | 8.78 | 14.41 | 2.97 | 6.23 | -7.06 |
| Return on Capital Employeed (%) | 14.70 | 19.78 | 9.85 | 10.99 | 2.83 |
| Return On Assets (%) | 3.86 | 6.73 | 1.18 | 2.71 | -2.80 |
| Long Term Debt / Equity (X) | 0.44 | 0.51 | 0.81 | 0.87 | 1.12 |
| Total Debt / Equity (X) | 0.95 | 0.80 | 0.95 | 1.04 | 1.20 |
| Asset Turnover Ratio (%) | 0.99 | 1.12 | 0.68 | 0.51 | 0.40 |
| Current Ratio (X) | 1.28 | 1.40 | 1.41 | 1.53 | 1.69 |
| Quick Ratio (X) | 0.73 | 0.73 | 0.55 | 1.05 | 0.97 |
| Inventory Turnover Ratio (X) | 5.63 | 2.47 | 2.37 | 0.72 | 0.53 |
| Interest Coverage Ratio (X) | 3.02 | 3.84 | 2.03 | 2.51 | 1.20 |
| Interest Coverage Ratio (Post Tax) (X) | 1.85 | 2.30 | 1.20 | 1.48 | 0.54 |
| Enterprise Value (Cr.) | 162.92 | 211.83 | 93.28 | 114.35 | 69.83 |
| EV / Net Operating Revenue (X) | 1.40 | 1.86 | 1.42 | 2.49 | 2.00 |
| EV / EBITDA (X) | 8.85 | 10.53 | 7.71 | 8.91 | 10.68 |
| MarketCap / Net Operating Revenue (X) | 0.95 | 1.54 | 0.84 | 1.64 | 0.87 |
| Price / BV (X) | 1.90 | 3.73 | 1.37 | 1.92 | 0.87 |
| Price / Net Operating Revenue (X) | 0.95 | 1.54 | 0.84 | 1.64 | 0.87 |
| EarningsYield | 0.04 | 0.03 | 0.02 | 0.03 | -0.08 |
After reviewing the key financial ratios for Lactose (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.10. This value is below the healthy minimum of 5. It has decreased from 5.39 (Mar 24) to 4.10, marking a decrease of 1.29.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.06. This value is below the healthy minimum of 5. It has decreased from 5.39 (Mar 24) to 4.06, marking a decrease of 1.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 8.38. This value is within the healthy range. It has decreased from 9.54 (Mar 24) to 8.38, marking a decrease of 1.16.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 46.66. It has increased from 37.41 (Mar 24) to 46.66, marking an increase of 9.25.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 46.66. It has increased from 37.41 (Mar 24) to 46.66, marking an increase of 9.25.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 92.46. It has increased from 90.47 (Mar 24) to 92.46, marking an increase of 1.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 14.63. This value is within the healthy range. It has decreased from 15.98 (Mar 24) to 14.63, marking a decrease of 1.35.
- For PBIT / Share (Rs.), as of Mar 25, the value is 10.34. This value is within the healthy range. It has decreased from 11.84 (Mar 24) to 10.34, marking a decrease of 1.50.
- For PBT / Share (Rs.), as of Mar 25, the value is 5.50. This value is within the healthy range. It has decreased from 7.68 (Mar 24) to 5.50, marking a decrease of 2.18.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.10. This value is within the healthy range. It has decreased from 5.39 (Mar 24) to 4.10, marking a decrease of 1.29.
- For PBDIT Margin (%), as of Mar 25, the value is 15.81. This value is within the healthy range. It has decreased from 17.66 (Mar 24) to 15.81, marking a decrease of 1.85.
- For PBIT Margin (%), as of Mar 25, the value is 11.18. This value is within the healthy range. It has decreased from 13.08 (Mar 24) to 11.18, marking a decrease of 1.90.
- For PBT Margin (%), as of Mar 25, the value is 5.94. This value is below the healthy minimum of 10. It has decreased from 8.48 (Mar 24) to 5.94, marking a decrease of 2.54.
- For Net Profit Margin (%), as of Mar 25, the value is 4.43. This value is below the healthy minimum of 5. It has decreased from 5.96 (Mar 24) to 4.43, marking a decrease of 1.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.78. This value is below the healthy minimum of 15. It has decreased from 14.41 (Mar 24) to 8.78, marking a decrease of 5.63.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.70. This value is within the healthy range. It has decreased from 19.78 (Mar 24) to 14.70, marking a decrease of 5.08.
- For Return On Assets (%), as of Mar 25, the value is 3.86. This value is below the healthy minimum of 5. It has decreased from 6.73 (Mar 24) to 3.86, marking a decrease of 2.87.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.44, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.95. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 0.95, marking an increase of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.99. It has decreased from 1.12 (Mar 24) to 0.99, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 1.5. It has decreased from 1.40 (Mar 24) to 1.28, marking a decrease of 0.12.
- For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.73.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.63. This value is within the healthy range. It has increased from 2.47 (Mar 24) to 5.63, marking an increase of 3.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.02. This value is within the healthy range. It has decreased from 3.84 (Mar 24) to 3.02, marking a decrease of 0.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.85. This value is below the healthy minimum of 3. It has decreased from 2.30 (Mar 24) to 1.85, marking a decrease of 0.45.
- For Enterprise Value (Cr.), as of Mar 25, the value is 162.92. It has decreased from 211.83 (Mar 24) to 162.92, marking a decrease of 48.91.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.40. This value is within the healthy range. It has decreased from 1.86 (Mar 24) to 1.40, marking a decrease of 0.46.
- For EV / EBITDA (X), as of Mar 25, the value is 8.85. This value is within the healthy range. It has decreased from 10.53 (Mar 24) to 8.85, marking a decrease of 1.68.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1. It has decreased from 1.54 (Mar 24) to 0.95, marking a decrease of 0.59.
- For Price / BV (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has decreased from 3.73 (Mar 24) to 1.90, marking a decrease of 1.83.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1. It has decreased from 1.54 (Mar 24) to 0.95, marking a decrease of 0.59.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lactose (India) Ltd:
- Net Profit Margin: 4.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.7% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.78% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.85
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 32.4 (Industry average Stock P/E: 42.99)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.95
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.43%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Survey No.5,6,7A, Vadodra District Gujarat 391780 | lil@lactoseindialimited.com http://www.lactoseindialimited.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Atul Maheshwari | Managing Director |
| Mrs. Sangita Maheshwari | WholeTime Director & CFO |
| Mr. Dhaval Jayant Soni | Ind. Non-Executive Director |
| Mr. Nandan Srinath | Ind. Non-Executive Director |
| Mr. Chandra Mohan Bhagavatula | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Lactose (India) Ltd?
Lactose (India) Ltd's intrinsic value (as of 19 December 2025) is 127.07 which is 9.54% higher the current market price of 116.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 147 Cr. market cap, FY2025-2026 high/low of 235/84.3, reserves of ₹50 Cr, and liabilities of 138 Cr.
What is the Market Cap of Lactose (India) Ltd?
The Market Cap of Lactose (India) Ltd is 147 Cr..
What is the current Stock Price of Lactose (India) Ltd as on 19 December 2025?
The current stock price of Lactose (India) Ltd as on 19 December 2025 is 116.
What is the High / Low of Lactose (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lactose (India) Ltd stocks is 235/84.3.
What is the Stock P/E of Lactose (India) Ltd?
The Stock P/E of Lactose (India) Ltd is 32.4.
What is the Book Value of Lactose (India) Ltd?
The Book Value of Lactose (India) Ltd is 49.6.
What is the Dividend Yield of Lactose (India) Ltd?
The Dividend Yield of Lactose (India) Ltd is 0.00 %.
What is the ROCE of Lactose (India) Ltd?
The ROCE of Lactose (India) Ltd is 12.9 %.
What is the ROE of Lactose (India) Ltd?
The ROE of Lactose (India) Ltd is 9.69 %.
What is the Face Value of Lactose (India) Ltd?
The Face Value of Lactose (India) Ltd is 10.0.